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Hepatocellular carcinoma (HCC) is a primary malignancy of the liver with poor prognosis 
and limited therapeutic options. Over the past few years, many studies have evaluated 
the role of non-coding RNAs (ncRNAs) in hepatocarcinogenesis and tumor progression. 
ncRNAs were shown to have diagnostic, prognostic, and therapeutic potential in HCC. 
In this manuscript, we review the latest major discoveries concerning microRNAs and 
long ncRNAs in HCC pathogenesis, and discuss the potentials and the limitations for 
their use in clinical practice.
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Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a primary tumor of the liver and represents the third cause of 
cancer deaths worldwide (1). Only few patients are eligible for curative treatments, while majority of 
cases are diagnosed at later stages (1). HCCs often arise on a background of liver cirrhosis and, as such, 
early diagnosis is frequently missed. Local ablative therapies, such as transarterial chemoembolization 
(TACE) and radiofrequency ablation (RFA), are used when the tumor is localized within the liver, 
while the multikinase-inhibitor sorafenib is the only approved systemic therapy for advanced HCC 
(2, 3). However, overall survival (OS) of patients affected by HCC remains poor. A growing effort 
has been addressed toward the study of genomics and molecular biology in order to unravel the 
mechanisms of liver carcinogenesis and therefore identifying novel targets of therapies as well as early 
diagnostic and prognostic markers to improve the clinical management of HCC patients. Along with 
an extensive characterization of the protein-coding genome of liver tumors (4–7), there has been a 
great interest in the study of non-coding RNAs (ncRNA). Hereby, we will review the role of ncRNA 
in liver carcinogenesis and their clinical implication.
non-coding RnAs in Hcc
Most of the eukaryotic genome is transcribed into RNA transcripts that do not translate into proteins. 
These RNA transcripts can be generally divided into two classes according to their size (with 200 nt 
as cut-off): short ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). 
Although they are not translated into protein products, they exert essential functions within the cell 
by modulating the expression of protein-coding mRNAs, interacting with proteins to affect their 
function, and interacting one with each other to finely tune their expression (8).
microRnAs
microRNAs are 18–24  nt long and represent key actors in the processes of tumor development, 
progression, and resistance to anti-tumor agents (9). Many studies have identified alterations in 
miRNAs in HCC (10–12). Some miRNAs, such as miR-21 and miR-221/222, were found increased 
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in expression, and acting as oncogenes by affecting several cancer-
related pathways (13–18). On the other hand, selected miRNAs, 
such as miR-26, miR-29, miR-122, miR-148a, and miR-199a, were 
reported to be reduced in HCC and to promote cancer by the lack 
of their oncosuppressive activity (19–24).
Data on the expression of miRNAs have mainly come from real 
time PCR-based and microarray-based profiling. More recently, the 
introduction of novel technologies, such as RNA next generation 
sequence (NGS) (RNA-seq), has led to the identification of novel 
miRNAs. NGS analysis produces miRNA expression profile that is 
reproducible and comparable to that produced by microarray, but 
has the advantage of discovering novel miRNAs (as for the case of 
miR-9986 for HCC), and of providing a detailed profile of expression 
of miRNA isoforms (25, 26). If down-regulation of miR-199a-3p in 
HCC was a solid data achieved through old technologies (27, 28), 
Wojcicka et al. showed through NGS that there are nine different 
isoforms of miR-199a-3p, which include three different seed regions. 
All the miR-199a-3p isoforms are lower in HCC tumors, and appar-
ently the gene targeting is conserved across the isoforms (26). These 
findings add interesting insights into the understanding of miRNAs, 
because they imply that the message delivered by each miRNA may 
be amplified according to the expression of their isoforms, and probe 
designing should take into account the variability among these.
Several reports have confirmed that the aberrant expression 
of miRNAs in HCC cells is associated with the derangement of a 
number of pathways and processes, which all together initiate and 
maintain cancer, promote cell growth, mediate apoptosis escape, 
and induce migration and invasion (Table 1). An example among 
TAble 1 | microRnAs involved in Hcc pathogenesis and development.
microRnA expression in 
Hcc compared  
to normal liver
Target cell phenotype source Reference
miR-21 Up PTEN, PDCD4, RECK, TIMP-3, Pellino-1 Growth, proliferation, invasion, 
and migration
Human tissues and cell lines (13, 14, 
29–31, 34)Mouse tissues and cell lines
miR-155 Up STAT-3, C/EBPbeta, SOX6, APC Growth, progression, and 
invasion
Human tissues and cell lines (138–142)
Mouse tissues and cell lines
miR-221/222 Up CDKN1C/p57, MET, Bmf,  
PI3K-AKT-mTOR, PPP2R2A, DDIT4, p27, 
p57, ARNT
Growth, cell-cycle progression, 
proliferation, invasion, and 
survival
Human tissues and cell lines (15–18, 70, 
143–146)Mouse tissues
miR-517 Up NF-kB, MAPK/ERK Proliferation, migration, and 
invasion
Human tissues (36)
miR-331-3p Up PHLPP Proliferation, migration, and 
invasion
Mouse tissues (68)
miR-664, miR-485, 
miR-495
Up MAT1A Growth, migration, and invasion Human cell lines (147)
Mouse tissues
miR-193b Down in HCC,  
Up in HCV-HCC  
cells
Mcl-1, Cyclin D1, ETS1 Apoptosis, invasion, migration, 
cell-cycle progression response 
to sorafenib
Human tissues and cell lines (79, 80, 
148)Mouse tissues
miR-199a-3p Down MET, ERK2, CD44 Motility, invasion, and survival Human tissues and cell lines (27, 28, 93)
Mouse tissues and cell lines
miR-26a Down Bcl-2, Mcl-1, Cyclins D1/E2/D2, CDK6, 
MMP2, MET, VEGFA, VEGFR-2, LOXL-2, 
IL6, TAK1, TAB3
Proliferation, migration, cell-cycle 
progression, invasion, motility, 
and survival
Human tissues and cell lines (19, 92, 
149–151)Mouse tissues
miR-29 Down DNMT3A, LOXL-2, MEG3, Bcl-2, Mcl-1, 
SIRT1
Cell growth, survival, and 
proliferation
Human tissues and cell lines (20, 41, 69, 
104)Mouse tissues
miR-148a Down DNMT1, MET, Myc, Snail, ACVR1/BMPs Growth, cell-cycle progression, 
invasion, and migration
Human tissues and cell lines (24, 40, 
152–154)Mouse tissues and cell lines
miR-122 Down Cyclin G1, ADAM10, SRF, IGFR1, Myc, 
CUTL1
Growth, cell-cycle, progression, 
proliferation, migration, invasion, 
and survival
Human tissues, cell lines and 
sera
(21, 38, 57, 
155–160)
Mouse tissues and cell lines
let-7 family Down Bcl-x, Type 1 collagen α, Myc, p16INK4A Proliferation, migration, and 
invasion
Human tissues and cell lines (161, 162)
ACVR1/BMPs, activin A receptor, type 1/bone morphogenetic proteins; ADAM10, a disintegrin and metalloproteinase domain-containing protein 10; APC, adenomatous polyposis 
coli; ARNT, Aryl hydrocarbon receptor nuclear translocator; Bcl-2, B-cell lymphoma 2; C/EBPbeta, CCAT/enhancer binding protein beta; CDKN1C, cyclin-dependent kinase inhibitor 
1C; DDIT4, DNA-damage inducible transcript 4; ERK, extracellular signal-regulated kinases; ETS1, v-ets avian erythroblastosis virus E26 oncogene homolog 1; IGFR-1, insulin 
growth factor receptor-1; LOXL2, lysil oxidase-like 2; MAPK, mitogen-activated protein kinase; MAT1A, methionine adenosyltransferase I, alpha; PHLPP, PH domain and leucine rich 
repeat protein phospathases; PPP2R2A, protein phosphatase 2, regulatory subunit B, alpha; SIRT-1, sirtuin-1; SRF, serum response factor; STAT-3, signal transducer and activator 
of transcription-3; TAB3, TGF-beta-activated kinase 1/MAP3K7 binding protein 3; TAK1, transforming growth factor beta-activated kinase 1; VEGFA, vascular endothelial growth 
factor A; VEGFR-2, vascular endothelial growth factor receptor-2.
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all is miR-21, whose over-expression results into the silencing of 
several targets including phosphatase and tensin homolog (PTEN), 
programed cell death protein 4 (PDCD4), reversion-inducing-
cysteine-rich protein with kazal motifs (RECK), metalloproteinase 
inhibitor 3 (TIMP-3), and Pellino-1 (13, 14, 29–31), but is concomi-
tantly finely tuned by a plethora of factors whose source can either 
be the tumor cell itself [nuclear factor kinase B (NF-KB), hepatitis 
B virus X protein (HBV x)] (32, 33), or microenvironment cells 
[interleukin-6 (IL-6) or monocyte chemotactic protein-1 (MCP-
1)] (33, 34). It is interesting to note that normal liver tissue seems 
to express a limited number of miRNAs, including miR-199a and 
miR-122 (35). Thus, it is not surprising that HCC tissues exhibit 
loss of these miRNAs along with over-expression of others, such 
as miR-21, miR-221/222, and miR-517 (13, 18, 36).
The mechanisms through which miRNA expression is modu-
lated during liver carcinogenesis are variable, and include chromo-
somal rearrangements, promoter methylation, and transcriptional 
induction through direct control of transcription factors such as 
Myc (9, 37–40). Recent evidence suggests that alpha-feto-protein 
(AFP) can alter miR-29 expression and can induce changes in the 
methylome of liver cancer cells that are responsible for the more 
aggressive behavior of AFP + HCC (41). Growing evidence show 
that nanovesicles-mediated delivery of miRNAs is another way of 
miRNA regulation and intercellular communication. Tumor cells 
were shown to actively secrete miRNAs through exosomes, which 
can then be internalized by other cells altering miRNA profiling, 
and modulating gene expression in donor cells (42, 43). Vacuolar 
protein sorting-associated protein 4A (Vps4A) has been identified 
as one of the regulators of exosome bioactivity, as it facilitates 
the release of exosome containing onco-miRs and alters the 
accumulation of those containing oncosuppressor miRNAs (44). 
miRNAs are highly conserved genes, and therefore, alterations of 
their sequence have been studied as potential causes of aberrant 
miRNA expression. It was observed that selected polymorphisms 
in miRNA genes might result in increased production of mature 
miRNA forms and therefore induce miRNA-dependent liver 
carcinogenesis. For instance, a G > C polymorphism located in the 
stem region of miR-146a is associated with increased predisposi-
tion to develop HCC (45). To date, polymorphisms in a number of 
miRNAs have been associated to increased risk of HCC (46–51). 
However, these studies have been carried out mainly in Chinese 
or Turkish populations, and their extrapolation to other ethnicities 
is not clear.
Clinical Implications of miRNAs in HCC
Diagnostic role
As previously discussed early diagnosis is one of the main 
challenges in the clinical management of HCC. miRNAs have 
shown to distinguish HCC from adjacent normal or cirrhotic 
tissues (18, 22, 36, 52). However, the main advances have been 
achieved through the detection of circulating miRNAs. Tissutal 
analyses are indeed a limitation in this field given HCC diagnosis 
is made on a combination of blood tests and imaging with no 
recommendation for mandatory biopsy in most of cases (1). 
Conversely, miRNAs can be detected in sera and plasma (53). 
They can circulate as free RNAs, which are bound to Argonaut 
RISC catalytic component 2 (Ago2) or included in exosomes; in 
either case, they are protected by RNases and remain stable after 
harsh conditions (54, 55). There are now a number of reports 
that showed miRNAs are detectable in the plasma and sera of 
HCC patients and their expression profile is different between 
patients with HCC and patients with cirrhosis, as reviewed by 
Roderburg et al. (56). The larger study includes a series of 934 
participants among healthy controls, and patients with chronic 
hepatitis B, cirrhosis, and hepatitis B virus (HBV)-related HCC 
(57). A panel of seven plasma miRNAs (miR-122, miR-192, miR-
21, miR-223, miR-26a, miR-27a, and miR-801) was shown to have 
a high-diagnostic accuracy of HCC. The diagnostic performance 
persisted regardless of disease stage and was able to differentiate 
HCC from healthy controls, chronic hepatitis B, and cirrhosis 
(57), suggesting a potential use of this panel in the early diagnosis 
of HBV-related HCC. However, it looks like circulating miRNA 
profiles differ according to the etiology, and therefore, these data 
cannot be extrapolated to all cases of HCC. Indeed, circulating 
miRNAs not only can distinguish patients who have developed 
HCC among all the HBV carriers but can also distinguish between 
patients with HBV and those with hepatitis C virus (HCV) (58), 
suggesting that specific miRNAs may be identified in each sub-
type of HCC. These data are not surprising given that (1) miRNA 
expression profiles were shown to be different in tissues from 
HBV-related versus HCV-related HCC (59), (2) miRNAs can 
facilitate replication of hepatitis viruses (60, 61), and (3) circulat-
ing miRNAs can reflect the status of liver injury in inflammatory 
diseases (62). Nonetheless, we need to remember that circulating 
miRNAs may also originate from blood cells, and therefore, an 
appropriate sample collection and processing, which excludes 
contamination by leukocytes and erythrocytes, is mandatory in 
this kind of analysis (63, 64). To date, lack of standardization 
of sample collection and data normalization, along with limited 
sample size in most of the reports impair the reproducibility and 
comparability across the studies. Thus, despite the interesting 
potential of circulating miRNAs as biomarker in HCC, further 
investigations are still warranted before they can be taken into 
clinical practice.
Prognostic role
microRNAs induce malignant phenotypic changes in liver cancer 
cells and contribute to the acquisition of invasive and metastatic 
properties (65, 66). Therefore, it comes with no surprise that their 
prognostic value has been widely investigated in HCC patients 
undergoing either curative treatments or local ablative therapies. 
Despite, Jiang et al. have initially postulated that a global loss of 
miRNA expression is associated with poorer clinical outcome (67), 
subsequent analyses in larger cohorts of patients identified single 
miRNAs as potential prognostic markers. Over-expression of 
oncogenic miRNAs, such as miR-331-3p (68) or down-regulation 
of oncosuppressive miRNAs, such as miR-29 (20, 69) has been 
associated to poor prognosis in unselected cohorts of human 
HCC tissues. High miR-221 levels were associated with tumor 
multifocality (15) and reduced time to recurrence after surgery 
(70). In addition, miR-221 was shown to have a prognostic value, 
with a significantly lower OS in patients with high-serum miRNA 
expression (71). Sato et  al. looked at miRNA expression in 73 
human resected HCCs that had not received any pre-operative 
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therapy and observed that miRNAs expression recapitulates the 
risk of early or late recurrence in analogy to mRNA profiles (6, 
72). The miRNA profile of tumoral tissue could predict early 
recurrence, while the miRNA profile of non-tumoral tissue was 
predictive of late recurrence and of de novo carcinogenesis. Ji 
et al. studied miRNA expression in a large (>400 cases) cohort of 
resected human HCC and observed a remarkable down-regulation 
of miR-26, which correlated with poor prognosis (19). Patients 
with high miR-26a expression had longer time to recurrence and 
longer OS. Despite having worse OS, patients with low miR-26 
expressing tumors had an increased benefit from adjuvant therapy 
with interferon (IFN)-alpha compared to those with tumors with 
high miR-26a. This was due to the parallel predominant activation 
of the signaling pathway NF-KB and IL-6 in this cohort of patients, 
with enhanced oncogenic potential. Thus, miR-26 expression acts 
not only as a prognostic factor but also as an independent predictor 
of the response to IFN-alpha (19). On the bases of these findings, 
a clinical trial is undergoing to look at the effect of adjuvant IFN 
in patients with HBV-related HCC and low miR-26 expression, 
and to our knowledge, this is the only clinical trial including 
miRNA expression as inclusion criteria or stratifying factor, to 
date. The possibility to detect circulating miRNAs in the sera/
plasma of liver cancer patients has recently increased the potential 
of studying the prognostic values of miRNAs in the clinical setting, 
resulting in a growing number of reports on the role of circulating 
miRNAs in predicting relapse after curative treatment. Sugimachi 
et al. observed that low expression of circulating exosome-related 
miR-718 was associated to poor histological differentiation, high 
incidence of tumors beyond the Milan criteria, and a trend to 
increased recurrence after liver transplantation (73). Some authors 
have suggested that serum miRNAs levels can be monitored after 
radical resection to assess disease relapse (74, 75), while others 
have noticed a correlation between serum levels of miR-200 and 
response to TACE (76). In addition, some studies have shown 
that miRNAs can affect survival by modulating invasiveness and 
metastasis, i.e., miR-135a was found over-expressed in portal vein 
thrombus tissues and was related to poor clinical outcome (77). 
Luk et al. (78) found that all miRNAs included in the DLK1–DIO3 
cluster at 14q32.2 are coordinately up-regulated in a subset of HCC 
patients with stem-like features, vascular invasion, and shorter 
survival. However, the limited sample size of these studies warrants 
further confirmations before these findings can be incorporated 
into clinical management.
Predictive role
Some miRNAs were found to be predictors of response to anti-
cancer therapy in HCC both in vitro and in vivo. We have shown 
that miR-193b can facilitate sorafenib-induced apoptosis through 
modulation of myeloid leukemia cell differentiation protein 
(Mcl-1) in human HCC cell lines (79). Similarly, restoration of 
miR-193b was shown to sensitize HBV+ HCC cells to sorafenib 
(80). However, expression of this miRNA in patient samples has 
not been investigated yet. Loss of miR-122 was associated to lower 
sensitivity of HCC cells to sorafenib in in vitro experiments (81). 
A retrospective analysis showed that high levels of miR-425-3p in 
HCC bioptic tissues were associated with longer time to progres-
sion and OS in patients treated with sorafenib (82). However, 
further prospective evaluation is needed before miRNAs can be 
used as stratifying factors for first line treatment. Moreover, given 
the lack of liver biopsies in the routine clinical setting studies on 
the role of circulating miRNAs on the prediction of response to 
sorafenib are likely to represent more useful tools to customize 
treatment.
Therapeutic role
Several approaches to normalize ncRNA expression have been 
described to date. Therapeutic inhibition of oncogenic miRNAs 
can be managed through different technologies. Antisense oli-
gonucleotides (ASO) are single-strand DNA molecules that pair 
to complementary RNA. They may be delivered intravenously 
but have poor stability (83). On the contrary, locked nucleic acid 
antimiRs (LNA-antimiRs) seem to be more stable and specific 
than ASO as they are composed of DNA and a phosphorothioate 
backbone (84). miRNA sponges contain binding site for several 
miRNAs and act as competitive inhibitors. They are potentially 
useful to inhibit a plethora of miRNAs that finally act on the same 
pathways, or a number of isoforms of the same miRNA (85). The 
best example of effective anti-miRNA therapy comes from the 
Miraversen studies. Miravirsen is a LNA-antimiR against miR-122, 
which is known to promote HCV RNA accumulation within the 
cells. Miraversen was tested in 36 patients with HCV genotype 
1 infection within a phase II clinical trial. Treatment resulted 
in a dose dependent and prolonged decrease of HCV RNA that 
lasted beyond the end of active therapy and was not associated 
with viral resistance and dose-limiting adverse events (86). Given 
the association noticed between reduced levels of miR-122 and 
development of liver cancer, the safety of anti-miR-122 therapy 
has been carefully evaluated, and none of the patients treated 
with Miravirsen were reported to have developed HCC or other 
liver-related complications (87).
With regards to HCC treatment, preclinical studies have been 
successful in achieving tumor growth inhibition through silenc-
ing of miR-221/222. MiR-221 and -222 are encoded in tandem 
from a gene cluster on the chromosome X (Xp11.3) and share the 
same 5′ region. They regulate and promote cell-cycle progression 
through down-regulation of cyclin-dependent kinase inhibitors 
(p27Kip1 and CDKN1C/p57) (88), and pro-apoptotic proteins 
Bcl-2-modifying factor (Bmf) (15), and can also modulate cell sur-
vival through controlling the phosphoinositide 3-kinase–protein 
kinase B–mammalian target of rapamycin (PI3K–AKT–mTOR) 
pathway (18). miR-221/222 is frequently up-regulated in human 
HCC and it was found to be associated with aggressive clinical 
features. Some reports suggest that MET induces miR-221/222 
transcription through the activator protein-1 (AP-1) transcrip-
tion factor, and that miR-221/222 can account for the aggressive 
biology of the “high MET” liver cancers (89). Intravenous delivery 
of cholesterol- and 2′-O-methyl phosphorothioate-modified anti-
miR-221 oligonucleotide (anti-miR oligonucleotide, AMO) led to 
reduced tumor cell proliferation, increased apoptosis, cell-cycle 
arrest, and increased survival in an orthotopic mouse model of 
HCC (90). Delivery of AMO anti-miR-221 confirmed anti-tumor 
effects in a transgenic mouse model over-expressing miR-221 in 
the liver, which spontaneously develops HCC and accelerates 
diethylnitrosamine-induced HCC growth (17). Interestingly, 
TAble 2 | long non-coding RnAs involved in Hcc pathogenesis and development.
lncRnA expression in Hcc  
compared to normal liver
cell phenotype source Reference
MEG3 Down Growth, reduced apoptosis Human tissues and cell lines (104–106)
Mouse tissues
MALAT-1 Up Growth, reduced apoptosis Human tissues, cell lines, plasma and sera (107, 108, 132, 137)
Mouse tissues
HOTAIR Up Progression, migration, invasion Human tissues (109, 110)
HOTTIP Up Progression, invasion Human tissues and cell lines (111)
HULC Up Proliferation Human tissues and cell lines (112, 134)
MVIH Up Invasion, migration Human tissues and cell lines (116)
RERT Up Hepatocarcinogenesis Human tissues and cell lines (117)
LincRNA-RoR Up Survival Human cell lines (118)
Mouse tissues
HEIH Up Cell-cycle progression Human tissues (119)
TUC338 Up Cell-cycle progression, cell growth Human tissues and cell lines (125)
Mouse cell lines
H19 Up Cells differentiation Human tissues (135)
Mouse tissues and cell lines
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three injections over a period of 30 days were sufficient to inhibit 
miR-221 expression and to cause HCC growth inhibition in this 
model (17). More recently, Callegari et al. have provided evidence 
that adeno-associated viruses (AAV) genetically modified to drive 
the expression of multiple binding sites for miR-221 can act as 
sponges that sequester miR-221 cellular molecules and exhibit 
anti-tumor activity in HCC cells and may be tested for in vivo 
miRNA inhibition (91).
miRNA-based therapeutics have also been developed to restore 
the expression of miRNAs, which are down-regulated in liver cancer. 
Delivery of miR-26 was attempted trough viral delivery in a mouse 
model of HCC and proved to be successful in inhibiting cancer 
cell proliferation, inducing of tumor-specific apoptosis, and block-
ing disease progression without liver toxicities (92). Intrahepatic 
delivery of an adenovirus expressing miR-199a in newborn mice 
led to virus replication and fast removal of implanted HepG2 liver 
cancer cells, as well as reduced tumor growth in different HCC 
mouse models (93). Selected evidences showed miR34a is lost in 
HCC and its expression has been linked to the status of p53 (94, 
95). Thus, attempts to over-express miR-34 have been pursued 
for the treatment of liver cancer. On one hand, a small molecular 
modulator termed Rubone, was shown to induce miR34a expres-
sion specifically in HCC cells by enhancing the occupancy of p53 
on the miR34a promoter, and showed anti-tumor activity in a xeno-
graft HCC mouse model (96). In p53 non-deleted HCC, Rubone 
exhibited a preclinical anti-HCC potency comparable to sorafenib 
without showing any additional toxicity (96). Therapeutics based 
on the restoration of miR-34 expression has also been pursued 
through liposome-mediated miRNA delivery technologies. Indeed, 
one ongoing phase I study is evaluating the safety of MRX34, a 
liposomal formulation of miR-34, in patients with primary HCC 
or those with liver metastases from other cancers (97). This is the 
first and only example of clinical trial, which assess miRNA-based 
therapeutics in humans, and results are highly expected from the 
scientific community. Therapies aiming at blocking or restoring 
miRNAs are promising and could become a new cornerstone in 
the treatment of HCC, either in monotherapy or in combination 
with sorafenib. However, additional investigations are needed to 
establish the real therapeutic benefit of these approaches, leading 
eventually to an improvement of survival in HCC.
long non-coding RnAs
Long non-coding RNAs can vary in length from 200 nt to 100 kb. 
Although the majority of lncRNAs have yet to be characterized 
thoroughly, they have been shown to exhibit cell type-specific 
expression, localization to subcellular compartments, and asso-
ciation with cancer. lncRNAs can be intronic or intergenic and 
can be transcribed either in sense or antisense. Their sequence is 
characterized by a paucity of introns and low-cytosine–guanine 
(CG) content, which may account for the low level of expression of 
these transcripts (98). In vitro analyses have shown that antisense 
and intergenic lncRNAs are more stable than others (99). Growing 
evidence is supporting the involvement of lncRNAs in carcino-
genesis. They may modulate cancer initiation and progression by 
affecting several biological pathways (100). However, their actual 
mechanism of function is not yet clear. Some evidence suggests 
that lncRNAs can modulate gene activity and affect the expression 
of other protein-coding genes. For instance, X-inactive specific 
transcript (XIST) was shown to modulate gene transcription by 
“coating Chromosome X” and creating a nuclear compartment 
that excludes RNA Polymerase-II (RNAPol-II) (101). Interaction 
with proteins has also been postulated, i.e., lncRNAs interact with 
the histone modification proteins and act as scaffold molecules for 
chromatin remodeling complexes (102). Growing evidence is now 
suggesting that lncRNAs can modulate the microRNome by bind-
ing one or multiple miRNAs and act like miRNA sponges (103).
Long Non-Coding RNAs in HCC
Long non-coding RNAs have been found to be aberrantly expressed 
in HCC and to play a role in modulating malignant phenotypes 
(Table 2). Maternally expressed gene 3 (MEG3) is an imprinted 
ncRNA located on chromosome 14q32.3 within the DLK-1 locus. 
We observed down-regulation of MEG3 in human HCC tissues in 
comparison to cirrhotic tissues secondary to hypermethylation of 
its promoter. In vitro experiments confirmed its oncosuppressive 
properties as over-expression of MEG3 reduced tumor cell growth 
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and induced apoptosis (104). A recent report confirmed down-
regulation of MEG3 in more than 70 cases of human HCC and 
found an association between low levels of MEG3 and poor clinical 
outcome with reduced overall and relapse-free survival (105). 
MEG3 was found to be the most frequently deregulated ncRNA in 
primary HCC when a set of 16 expression profiles from Oncomine 
comprising altogether 953 primary human HCC specimens was 
analyzed (106). Indeed, it was down-regulated in 60% of cases and 
there was correlation between increased DNA methylation and 
reduced MEG3 expression. Interestingly, no alterations in DNA 
methylation at the DLK1-MEG3 imprinting locus were found in 
hepatocellular adenomas or focal nodular hyperplasia. The meta-
static lung adenocarcinoma transcript 1 (MALAT-1) is a lncRNA 
located on chromosome 11q13.1 that was initially identified in 
metastatic lung cancer and was then found increased in a mouse 
model of HCC as well as in human HCC cell lines and tissues (107, 
108). MALAT-1 seems to mediate carcinogenesis by modulating 
apoptosis and cell growth in HCC cell lines and its expression 
correlates with risk of recurrence after liver transplantation (107). 
HOX transcript antisense RNA (HOTAIR) is expressed from the 
developmental HOX-C locus located on chromosome 12q13.13. 
HOTAIR expression was found increased in patients with large 
primary HCC and those with nodal involvement (109, 110). It acts 
as an oncogene, which may positively regulate the expression levels 
of multiple genes involved in the promotion of metastatic process, 
such as vascular endothelial growth factor (VEGF) and matrix 
metallopeptidase 9 (MMP9) (109). HOTAIR acts as a scaffolding 
molecule that binds polycomb repressive complex 2 (PRC2) and 
lysine-specific demethylase 1 (LSD1) and increases recruitment of 
enzymes involved in the epigenetic modification, with subsequent 
repression of tumor suppressor genes (102). HOXA transcript at 
the distal tip (HOTTIP) is another lncRNA located in physical 
contiguity with a HOX locus. HOTTIP is located at the distal tip 
of the HOXA13 gene, which encodes transcription factors regulat-
ing embryonic development. HOTTIP directly controls HOXA 
locus gene expression, but is also controlled by HOXA13 showing 
that a fine regulatory feedback loop is necessary for its activation 
(111). HOTTIP is remarkably increased in human HCC tissues 
from liver biopsies and its expression predicts clinical outcome 
in patients who had not received any HCC treatments, suggest-
ing that liver biopsy may be an important source of information 
for the understanding of molecular biology of inoperable HCC 
and for the definition of molecular prognostic markers. Highly 
up-regulated in liver cancer (HULC) is a <500 nt lncRNA, which 
show high conservation across species (112). It is present in the 
cytoplasm of liver cancer cells, where it localizes within the ribo-
somes, suggesting it may modulate translational activity. Indeed, 
silencing of HULC in HCC cells-induced global mRNA changes 
in genes involved in hepatocarcinogenesis (112). Interestingly, 
not only HULC increased in liver cancer tissues but was also 
found to be increased in cells from peripheral bloods of HCC 
patients, suggesting that its involvement in liver cancer may be 
exerted also through a modulation of the immune system. HULC 
expression positively correlates with that of HBV x. HBV x was 
shown to upregulate HULC, which in turn promotes proliferation 
of hepatoma cells by suppressing the oncosuppressor p18 (113). 
In other studies, HULC was shown to promote hepatoma cells 
proliferation by modulation of lipid metabolism (114). Moreover, a 
particular variant genotype (rs 7763881) in HULC has been found 
to contribute to decreased HCC development in HBV+ patients 
(115). Microvascular invasion in HCC (MVIH) is a long ncRNA 
independently transcribed in human HBV-related HCC tissues 
compared to adjacent normal counterparts (116). Over-expression 
of MVIH correlated to microvessel invasion, advanced stage, and 
poorer OS in a large and unselected cohort of human HBV–HCC 
patients. Interestingly, MVIH could also significantly predict 
relapse in patients with early HCC who underwent radical treat-
ment. In vitro experiments have shown that MVIH can physically 
interact with the protein phosphoglycerate kinase 1 (PGK1), an 
anti-angiogenic protein. It looks like the interaction results in 
reduced secretion of PGK1, and enhancement of angiogenesis 
and tumor growth. Indeed, MVIH expression in the primary 
tumor inversely correlated with PGK1 levels in serum of HCC 
patients (116). RERT is an lncRNA whose sequence overlaps with 
that of Prolyl-hydroxylase 1 (EGLN2) (117). EGLN2 is one of the 
three enzymes able to determine degradation of hypoxia inducible 
factor (HIF) by poly-ubiquitylation and proteasomal degradation. 
It was shown that a 4-bp deletion polymorphism (rs10680577) 
within RERT significantly correlated with higher expression of 
RERT and subsequent up-regulation of EGLN2 in human HCC 
(117). Finally, EGLN2 over-expression made cells more sensitive 
to hypoxia stress, leading to less HIF-alpha stabilization and HIF 
activation, which were detrimental for hepatic cell survival. These 
findings provided an example of how up-regulation of lncRNA can 
promote hepatocarcinogenesis through regulation of transcription 
of close genes and modulation of cell response to stress (117). Long 
intergenic ncRNA regulator of reprograming (lincRNA-RoR) is 
another hypoxia-responsive lncRNA, which is increased in malig-
nant human liver cancer cells, and in the hypoxic regions of tumor 
cell xenografts in vivo (118). Interestingly, linc-ROR was detected 
in extracellular vesicles released by tumor cells during hypoxia, 
suggesting that this lncRNA may contribute to the intercellular 
signaling promoting cell survival in hypoxic stress (118). High 
expression in HCC (HEIH) is an lncRNA identified in human 
liver tissues and was named after its over-expression in human 
HBV–HCC compared to cirrhotic samples (119). It was shown 
to act as an oncogene in vitro and in vivo models and was found 
to interact with the enhancer of zeste homolog 2, an essential 
subunit of PRC2 complex. HEIH over-expression was found 
significantly associated with higher recurrence in HBV–HCC 
patients and was an independent prognostic factor for OS (119). 
lincRNA–UFC1 was found over-expressed in HCC tissues and 
associated with advanced stages and poor clinical outcome (120). 
lincRNA–UFC1 seems to control expression of beta-catenin not 
by direct interaction but through the binding to HuR, a RNA-
binding proteins that can in turn interact with beta-catenin mRNA. 
Interestingly, lincRNA–UFC1 was also found to be a direct target 
of miR-34, whose loss in HCC was postulated to be the driver of 
lincRNA–UFC1 over-expression (120).
Transcribed Ultra-Conserved Regions
Ultra-conserved regions (UCRs) comprise 481 genomic sequences 
longer than 200 bp, which are totally conserved among mouse, 
rat, and human genomes (121). SNPs and mutations are normally 
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under-represented in UCR genes (122). Many UCRs are tran-
scribed (T-UCRs) in normal human tissue (123). Some of them 
have a ubiquitous expression, while others are tissue-specific (124). 
T-UCRs were shown to have distinct genome-wide expression 
profiles in different human cancers and this evidence supports their 
role in human carcinogenesis (123–127). The function of T-UCRs 
is still partly unknown, but they seem to modify the microRNome 
of the cell (128). Several mechanisms may be responsible for 
the deregulation of T-UCRs, including promoter methylation 
(127) and transcriptional activation (123). T-UCRs have been 
investigated in HCC and their expression profile was found to be 
deregulated in malignant compared to normal hepatocytes (125). 
The ultra-conserved element 338 (uc.338) is partly overlapping a 
protein-coding gene but was found to be transcribed as part of an 
independent lncRNA (TUC338). TUC338 expression is increased 
in human and murine malignant hepatocytes as well as in human 
HCC tissues in comparison to normal liver. Interestingly, not 
only the sequence but also the functional activity in promoting 
cellular growth is conserved across the species, suggesting that 
TUC338 is essential for the normal homeostasis of liver cells and 
that its aberrant over-expression may be responsible for driving 
carcinogenesis (125). Kogure et al. have also demonstrated that 
T-UCRs can be found in extracellular vesicles secreted by cancer 
cells, strengthening the hypothesis that they exert an important 
role in modulating tumor cell growth and they are part of the 
intercellular signaling through which HCC may grow and spread 
(129). Growing evidence is supporting the role of T-UCRs also in 
other types of cancer (124, 126, 130), and given their conservation 
it is likely that they play an essential part in driving carcinogenesis 
and may therefore represent valuable targets for novel therapeutics.
interactions between lncRnAs and miRnAs
Recent evidence suggests that miRNAs and lncRNAs are likely to 
modulate each other by acting in a complex network. miRNAs can 
directly or indirectly regulate the expression of lncRNAs. Calin 
et al. showed that miRNAs can bind to the sequence of lncRNAs 
and negatively regulate their expression (123). MALAT-1 was 
found to be a target of miR-125b, which can directly bind the 
lncRNA and control its expression in bladder cancer (131). Over-
expression of MALAT-1 (107) and down-regulation of miR-125 
(132) have been separately reported in human HCC, suggesting 
that this mechanism may account for up-regulation of MALAT-1 
in liver cancer as well. miRNAs were shown to control lncRNA 
expression also through indirect mechanisms. For instance, the 
miRNA-dependent control of the methylation machinery may 
have implications on the oncogenic role of selected lncRNAs in 
HCC. This is the case of MEG3 and miR-29. MiR-29 can modulate 
de novo methyltranferase (DMNT) 1 and 3. In case of low expres-
sion of miR-29, methylation-dependent tissue-specific regulation 
of MEG3 does not occur, and the lncRNA is suppressed (104).
If miRNAs can regulate lncRNAs, there is also evidence that 
lncRNAs may, in turn, regulate miRNAs by acting as competing 
endogenous RNAs or by being processed into small RNAs (133). 
HULC was shown to have binding sites for miR-372 and therefore 
to act as an endogenous “sponge.” HULC-mediated inhibition 
of miR-372 leads to reduction in repression of the target gene 
PRKACB and subsequent phosphorylation of the proto-oncogene 
c-AMP response element-binding protein (CREB) in HCC cells 
(134). Linc-RoR, a hypoxia-induced lncRNA, was shown to deplete 
HCC cells from miR-145 in hypoxic conditions and to mediate its 
biological effect through the interaction with miRNAs (118). Liz 
et al. have recently provided solid evidence that T-UCR can affect 
miRNA processing by preventing the release of mature forms. 
Indeed, uc.283 was shown to interact with the lower stem region 
of pri-miR-195 transcript preventing the miRNA cleavage by 
Drosha (128). Some authors have reported that the lncRNA H19, 
observed to be up-regulated in HCC (135), can mediate muscle 
differentiation by releasing miR-675, which is encoded within its 
sequence (136). Ren et  al. have speculated that MALAT-1 can 
be fragmented in several small RNAs that can then be released 
from cancer cells and found in the plasma of HCC patients (137). 
Despite growing evidence is reported on the interplay between 
different classes of ncRNAs, further investigation is warranted in 
order to better understand the function of ncRNA and exploit 
their potential as therapeutic targets.
conclusion
Non-coding RNAs participate in genomic regulation from 
transcription, post-transcription, and epigenetic modification. 
They can interact with each other and create networks of signal 
transduction that have a crucial role in hepatocarcinogenesis and 
disease progression. Moreover, they may modulate cell response 
to anticancer agents and have an intrinsic antineoplastic effect 
complementary to that of systemic therapies. In recent years, a 
large number of ncRNAs have been identified and several studies 
have investigated the role of ncRNA in HCC providing valuable 
knowledge for the understanding of liver carcinogenesis. However, 
despite the increasing knowledge on ncRNAs in liver cancer, none 
of them has entered clinical practice, and only few phase I and II 
trials have been conducted up to now. The process of translation 
of preclinical results into clinic seems challenging and hard to 
pursue. Indeed, the safety of ncRNAs as clinical therapeutic targets 
needs to be established with certainty. For example, the use of 
viral delivery systems may activate the innate immune responses 
with subsequent serious adverse events, while targeting ncRNAs 
involved in regulation of gene expression could bring to unex-
pected off target gene effects. Moreover, modulation of miRNA 
expression and competition with endogenous miRNAs may have 
unexpected effects on cellular physiology.
Hepatocellular carcinoma has still poor prognosis and limited 
therapeutic options. To date, only one drug, sorafenib, has been 
approved for first line treatment, and several trials investigating 
novel drugs have failed. Several ncRNAs directly involved in 
HCC promotion and progression have been effectively targeted 
in preclinical studies. It is hoped that these efforts will be soon 
translated into clinical practice.
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